Combining population health and baseline risk strategy by determining an age cutoff for initiating statins in patients with diabetes: A population-based study

Diabetes Care

Volumn 30, Issue 8, 2007, Pages 2025-2029

  Siyambalapitiya, Sajith ^a,b   Bulugahapitiya, Uditha ^a,b   Sithole, Jabulani ^c   Song, Soon ^b,d   Fernando, Devaka J S ^a,b,e   Idris, Iskandar ^a,b  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d NORTHERN GENERAL HOSPITAL   (United Kingdom)

^e SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DIABETES MELLITUS; DRUG COST; DRUG INDICATION; FEMALE; HEALTH PROGRAM; HUMAN; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POPULATION RESEARCH; PREVALENCE; PRIMARY PREVENTION; RISK FACTOR; RISK MANAGEMENT; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 34547689658     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0439     Document Type: Article

References (29)

1. Whitely L, Padmanathan S, Hole D, Isles C: Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley Survey. Diabetes Care 28:1588-1593, 2005
2. Emberson J, Whincup P, Morris R, Walker M, Ebrahim S: Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 25:484-491, 2004
3. Collins R, Armitage J, Parish S, Sleight P, Peto R: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, CARDS Investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685-696, 2004
5. Robins SJ: Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr Opin Lipidol 14:575-583, 2003
6. Knopp RH, d'Emden M, Smilde JG, Pocock SJ: Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) Diabetes Care 29:1478-1485, 2006
7. National Institute for Clinical Excellence: Management of Type 2 Diabetes: Management of Blood Pressure and Blood Lipids. London, National Institute for Clinical Excellence, 2002
8. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 2:120-126, 1979
9. Roland MO: Linking physicians' pay to the quality of care: a major experiment in the United Kingdom. N Engl J Med 351:1448-1454, 2004
10. Joint British Society: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (Suppl. 5):v1-v52, 2005
11. Yorkshire and Humber Public Health Observatory (YHPBO) [Internet], 2007. Heslington, York, U.K. Available from: http://www.yhpho.org.uk/. Accessed 27 January 2006
12. Bourke A, Dattani H, Robinson M: Feasibility study and methodology to create a quality evaluated database of primary care data. Inform Prim Care 12:171-177, 2004
13. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL: Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research Pharmacoepidemiol Drug Saf 16:393-401, 2007
14. Anderson KM, Odell PM, Wilson PWF, Kannel WB: Cardiovascular disease risk profiles. Am Heart J 121:292-298, 1991
15. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR: The UKPDS risk engine, a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 101:671-679, 2001
16. Yeo WW, Yeo KR: Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341-344, 2001
17. Song SH, Brown PM: Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 21:238-245, 2004
18. Moon JC, Bogle RG: Switching statins. BMJ 332:1344-1345, 2006
19. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
20. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C: low-dose aspirin for the prevention of atherothrombosis. N Eng J Med 353:2373-2383, 2005
21. Booth GL, Kapral MK, Fung K, Tu JV: Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 368:29-36,2006
22. Lee JD, Morrissey JR, Mikhailidis DP, Patel V: CARDS on the table: should everybody with type 2 diabetes take a statin? Curr Med Res Opin. 21:357-562, 2005
23. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction N Engl J Med 339:229-234, 1998
24. Evans JMM, Wang J, Morris AD: Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 163:939-943, 2002
25. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB: The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol 40:954-960, 2002
26. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM: BHS guidelines working party for the British Hypertension Society Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18:139-185, 2004
27. Royal College of Physicians of Edinburgh Diabetes Register Group: Predicting vascular risk in type 1 diabetes: stratification in a hospital based population in Scotland. Diabet Med 22:164-171, 2005
28. Ramachandran S, French JM, Vanderpump MPJ, Croft P, Neary RH: Using the Framingham model to predict heart disease in the United Kingdom: retrospective study. BMJ 320:767-777, 2000
29. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD: Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 22:554-562,2005